Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms
Alexandra E Livanos,Divya Jha,Francesca Cossarini,Ana S Gonzalez-Reiche,Minami Tokuyama,Teresa Aydillo,Tommaso L Parigi,Mark S Ladinsky,Irene Ramos,Katie Dunleavy,Brian Lee,Rebekah E Dixon,Steven T Chen,Gustavo Martinez-Delgado,Satish Nagula,Emily A Bruce,Huaibin M Ko,Benjamin S Glicksberg,Girish Nadkarni,Elisabet Pujadas,Jason Reidy,Steven Naymagon,Ari Grinspan,Jawad Ahmad,Michael Tankelevich,Yaron Bram,Ronald Gordon,Keshav Sharma,Jane Houldsworth,Graham J Britton,Alice Chen-Liaw,Matthew P Spindler,Tamar Plitt,Pei Wang,Andrea Cerutti,Jeremiah J Faith,Jean-Frederic Colombel,Ephraim Kenigsberg,Carmen Argmann,Miriam Merad,Sacha Gnjatic,Noam Harpaz,Silvio Danese,Carlos Cordon-Cardo,Adeeb Rahman,Robert E Schwartz,Nikhil A Kumta,Alessio Aghemo,Pamela J Bjorkman,Francesca Petralia,Harm van Bakel,Adolfo Garcia-Sastre,Saurabh Mehandru,Alexandra E. Livanos,Ana S. Gonzalez-Reiche,Tommaso L. Parigi,Mark S. Ladinsky,Rebekah E. Dixon,Steven T. Chen,Emily A. Bruce,Huaibin M. Ko,Benjamin S. Glicksberg,Graham J. Britton,Matthew P. Spindler,Jeremiah J. Faith,Robert E. Schwartz,Nikhil A. Kumta,Pamela J. Bjorkman
DOI: https://doi.org/10.1053/j.gastro.2021.02.056
IF: 29.4
2021-06-01
Gastroenterology
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS">Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of COVID-19, we investigated intestinal infection with SARS-CoV-2, its effect on pathogenesis, and clinical significance.</AbstractText>METHODS: <AbstractText Label="METHODS">Human intestinal biopsy tissues were obtained from patients with COVID-19 (n = 19) and uninfected control individuals (n = 10) for microscopic examination, cytometry by time of flight analyses, and RNA sequencing. Additionally, disease severity and mortality were examined in patients with and without GI symptoms in 2 large, independent cohorts of hospitalized patients in the United States (N = 634) and Europe (N = 287) using multivariate logistic regressions.</AbstractText>RESULTS: <AbstractText Label="RESULTS">COVID-19 case patients and control individuals in the biopsy cohort were comparable for age, sex, rates of hospitalization, and relevant comorbid conditions. SARS-CoV-2 was detected in small intestinal epithelial cells by immunofluorescence staining or electron microscopy in 15 of 17 patients studied. High-dimensional analyses of GI tissues showed low levels of inflammation, including down-regulation of key inflammatory genes including IFNG, CXCL8, CXCL2, and IL1B and reduced frequencies of proinflammatory dendritic cells compared with control individuals. Consistent with these findings, we found a significant reduction in disease severity and mortality in patients presenting with GI symptoms that was independent of sex, age, and comorbid illnesses and despite similar nasopharyngeal SARS-CoV-2 viral loads. Furthermore, there was reduced levels of key inflammatory proteins in circulation in patients with GI symptoms.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">These data highlight the absence of a proinflammatory response in the GI tract despite detection of SARS-CoV-2. In parallel, reduced mortality in patients with COVID-19 presenting with GI symptoms was observed. A potential role of the GI tract in attenuating SARS-CoV-2-associated inflammation needs to be further examined.</AbstractText>
gastroenterology & hepatology